SG11201600102SA - Method of treating hypertrophic cardiomyopathy - Google Patents
Method of treating hypertrophic cardiomyopathyInfo
- Publication number
- SG11201600102SA SG11201600102SA SG11201600102SA SG11201600102SA SG11201600102SA SG 11201600102S A SG11201600102S A SG 11201600102SA SG 11201600102S A SG11201600102S A SG 11201600102SA SG 11201600102S A SG11201600102S A SG 11201600102SA SG 11201600102S A SG11201600102S A SG 11201600102SA
- Authority
- SG
- Singapore
- Prior art keywords
- hypertrophic cardiomyopathy
- treating hypertrophic
- treating
- cardiomyopathy
- hypertrophic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361861359P | 2013-08-01 | 2013-08-01 | |
| PCT/US2014/048495 WO2015017351A1 (en) | 2013-08-01 | 2014-07-28 | Method of treating hypertrophic cardiomyopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201600102SA true SG11201600102SA (en) | 2016-02-26 |
Family
ID=51352822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201600102SA SG11201600102SA (en) | 2013-08-01 | 2014-07-28 | Method of treating hypertrophic cardiomyopathy |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9125916B2 (ja) |
| EP (1) | EP3027189A1 (ja) |
| JP (1) | JP2016525575A (ja) |
| KR (1) | KR20160035060A (ja) |
| CN (1) | CN105473143A (ja) |
| AU (1) | AU2014296477A1 (ja) |
| CA (1) | CA2919669A1 (ja) |
| EA (1) | EA201690214A1 (ja) |
| HK (1) | HK1222571A1 (ja) |
| MX (1) | MX2016001301A (ja) |
| NZ (1) | NZ715554A (ja) |
| SG (1) | SG11201600102SA (ja) |
| WO (1) | WO2015017351A1 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170007617A1 (en) * | 2015-07-09 | 2017-01-12 | Gilead Sciences Drive | Intravenous formulations of a late sodium current inhibitor |
| US20180064726A1 (en) * | 2016-09-08 | 2018-03-08 | Auspex Pharmaceuticals, Inc. | Deuterium-Substituted Oxazepin Compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI622583B (zh) * | 2011-07-01 | 2018-05-01 | 基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| US20150045305A1 (en) * | 2012-01-27 | 2015-02-12 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
-
2014
- 2014-07-28 EA EA201690214A patent/EA201690214A1/ru unknown
- 2014-07-28 SG SG11201600102SA patent/SG11201600102SA/en unknown
- 2014-07-28 AU AU2014296477A patent/AU2014296477A1/en not_active Abandoned
- 2014-07-28 CN CN201480038688.0A patent/CN105473143A/zh active Pending
- 2014-07-28 KR KR1020167005010A patent/KR20160035060A/ko not_active Application Discontinuation
- 2014-07-28 JP JP2016531802A patent/JP2016525575A/ja active Pending
- 2014-07-28 CA CA2919669A patent/CA2919669A1/en active Pending
- 2014-07-28 WO PCT/US2014/048495 patent/WO2015017351A1/en active Application Filing
- 2014-07-28 MX MX2016001301A patent/MX2016001301A/es unknown
- 2014-07-28 NZ NZ715554A patent/NZ715554A/en not_active IP Right Cessation
- 2014-07-28 EP EP14750903.8A patent/EP3027189A1/en not_active Withdrawn
- 2014-07-28 US US14/444,796 patent/US9125916B2/en active Active
-
2016
- 2016-09-13 HK HK16110817.2A patent/HK1222571A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201690214A1 (ru) | 2016-07-29 |
| AU2014296477A1 (en) | 2016-01-28 |
| HK1222571A1 (zh) | 2017-07-07 |
| EP3027189A1 (en) | 2016-06-08 |
| CN105473143A (zh) | 2016-04-06 |
| MX2016001301A (es) | 2016-04-07 |
| KR20160035060A (ko) | 2016-03-30 |
| NZ715554A (en) | 2017-01-27 |
| WO2015017351A1 (en) | 2015-02-05 |
| US9125916B2 (en) | 2015-09-08 |
| JP2016525575A (ja) | 2016-08-25 |
| CA2919669A1 (en) | 2015-02-05 |
| US20150038487A1 (en) | 2015-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1217908A1 (zh) | 治療膽管癌的方法 | |
| PT2992908T (pt) | Método para tratamento da superfície do implante | |
| GB201401248D0 (en) | Method of manufacture | |
| ZA201506534B (en) | Method of treating hair | |
| EP2968273A4 (en) | METHOD FOR THE TREATMENT OF MUSCLE DYSTROPHIES | |
| GB201412190D0 (en) | Method of optimization for an application | |
| HUE042470T2 (hu) | Eljárás széntartalmú anyagok kezelésére gõz termolízissel | |
| HK1224230A1 (zh) | 治療細胞內感染的方法 | |
| PL2837678T3 (pl) | Sposób ulepszonego wytapiania tłuszczu | |
| EP2968366A4 (en) | METHODS OF TREATING TESTOSTERONE DEFICIENCY | |
| EP2941270A4 (en) | METHODS FOR TREATING INFLAMMATION | |
| GB201305231D0 (en) | Method of Manufacture | |
| IL241096A0 (en) | Treatment methods | |
| EP2961401A4 (en) | METHOD FOR TREATING OTOTOXICITY | |
| GB201308466D0 (en) | Improved process for treatment of minewater | |
| PL3082860T3 (pl) | Sposób leczenia ran | |
| HK1222571A1 (zh) | 治療肥厚性心肌病的方法 | |
| EP3035925A4 (en) | Method for treating neuropathic pain | |
| IL243443A0 (en) | A method for reducing strontium concentration | |
| PL3041506T3 (pl) | Sposób leczenia | |
| HK1224331A1 (zh) | 治療尿路上皮癌的方法 | |
| GB2523221B (en) | Method of isolating ions | |
| GB201322778D0 (en) | Method of treatment | |
| GB201314882D0 (en) | Method of treatment | |
| GB201303264D0 (en) | Method of control |